In addition, you must meet one of the three clinical criteria set by CMS, measured at the time you start GLP-1 therapy: BMI of 35 or higher (and age 18 or older), or BMI of 30 or higher (and age 18 or older), plus one of the following: heart failure with preserved ejection fraction, uncontrolled high blood pressure (systolic above 140 or diastolic above 90 despite treatment with two blood pressure medications), or chronic kidney disease stage 3a or above, or BMI of 27 or higher (and age 18 or older), plus one of the following: prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease If you take a GLP-1 for another condition, the Bridge is not for you
65 Does the paradox that either GIPR agonist or antagonist exhibits benefits in combination with GLP-1R agonist correlates with the likely reduction of internalization, following the decrement of -arrestin recruitment or the acceleration of the dissociation rate (K off ) between the ligand and receptor, owing to competition between used agonists and antagonists in endogenous GIP
Ann N Y Acad Sci (1999) 885:27786
Just like any other prescription medication, both Ozempic and metformin have their own drug interactions and potential warnings
Berberine does not directly block or reduce semaglutide's effectiveness at the GLP-1 receptor
